Literature DB >> 10397414

Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls.

L Flyckt1, O Sydow, L Bjerkenstedt, G Edman, E Rydin, F A Wiesel.   

Abstract

Schizophrenic patients (DSM-III-R) were consecutively recruited and 39 were included. Twenty-one were first-episode and 18 were chronic schizophrenic patients. Thirty of the patients were on neuroleptic medication. Thirty-three parents were included, of whom nine were classified as 'family history positive' and 22 as 'family history negative' of a disposition to psychosis. Fifty-five healthy controls volunteered. The subjects were investigated according to a protocol divided into neurological signs and psychomotor performance (finger-tapping rate, Purdue pegboard test, pronation-supination test, gait and hand-grasp strength). Seventy-eight percent of the patients and 7% of the controls were classified as globally aberrant in signs. The patients and their parents, classified as 'family history positive', exhibited a similar laterality pattern in a finger-tapping test improving performance with the preferred hand, significantly different from the performance of the 'family history negative' parents and normal subjects. Duration of illness, neuroleptic medication and negative symptoms were not related to the occurrence of neurological signs and psychomotor performance. These findings indicate that neurological aberrations are present at the onset of illness and that hereditary factors are associated with motor laterality.

Entities:  

Mesh:

Year:  1999        PMID: 10397414     DOI: 10.1016/s0165-1781(99)00027-x

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  23 in total

1.  Premorbid multivariate markers of neurodevelopmental instability in the prediction of adult schizophrenia-spectrum disorder: a high-risk prospective investigation.

Authors:  Shana Golembo-Smith; Jason Schiffman; Emily Kline; Holger J Sørensen; Erik L Mortensen; Laura Stapleton; Kentaro Hayashi; Niels M Michelsen; Morten Ekstrøm; Sarnoff Mednick
Journal:  Schizophr Res       Date:  2012-06-02       Impact factor: 4.939

2.  Reflexes in psychiatry.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Innov Clin Neurosci       Date:  2011-04

3.  Gait and its assessment in psychiatry.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Psychiatry (Edgmont)       Date:  2010-07

4.  Motor examinations in psychiatry.

Authors:  Richard D Sander
Journal:  Psychiatry (Edgmont)       Date:  2010-11

Review 5.  Psychomotor slowing in schizophrenia.

Authors:  Manuel Morrens; Wouter Hulstijn; Bernard Sabbe
Journal:  Schizophr Bull       Date:  2006-11-08       Impact factor: 9.306

6.  Cranial Nerves III, IV, and VI: Oculomotor Function.

Authors:  Richard D Sanders
Journal:  Psychiatry (Edgmont)       Date:  2009-11

7.  More than just tapping: index finger-tapping measures procedural learning in schizophrenia.

Authors:  Felipe N Da Silva; Farzin Irani; Jan Richard; Colleen M Brensinger; Warren B Bilker; Raquel E Gur; Ruben C Gur
Journal:  Schizophr Res       Date:  2012-02-16       Impact factor: 4.939

8.  Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis.

Authors:  Jeroen P F Koning; Diederik E Tenback; Jim van Os; André Aleman; René S Kahn; Peter N van Harten
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

9.  Neurological soft signs in schizophrenia: a meta-analysis.

Authors:  Raymond C K Chan; Ting Xu; R Walter Heinrichs; Yue Yu; Ya Wang
Journal:  Schizophr Bull       Date:  2009-04-17       Impact factor: 9.306

10.  Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.

Authors:  Patrik Roser; Jürgen Gallinat; Gordon Weinberg; Georg Juckel; Inge Gorynia; Andreas M Stadelmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-02-17       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.